Trial Profile
A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 256073 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 18 May 2011 New trial record